Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10759034 | 0.93 | SMYD2 (0.43) | MAPTSMYD2SMN1; SMN2HTTKDM4E | |
| SCHEMBL18312814 | 0.78 | DUT (0.40) | MAPTSMN1; SMN2HTTKDM4EALDH1A1 | |
| SCHEMBL28735718 | 0.76 | MEN1 (0.49) | SMYD2SMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL554235 | 0.76 | SIGMAR1 (0.49) | MAPTSMYD2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5482915 | 0.75 | PER2 (0.39) | SMYD2SMN1; SMN2HTTPER2CYP3A4 | |
| SCHEMBL21594856 | 0.74 | NT5E (0.36) | MAPTSMYD2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10750226 | 0.73 | SMYD2 (0.40) | SMYD2SMN1; SMN2HTTALDH1A1CYP3A4 | |
| SCHEMBL5482922 | 0.72 | SMYD2 (0.38) | MAPTSMYD2SMN1; SMN2ALDH1A1PER2 | |
| SCHEMBL3757378 | 0.71 | SMYD2 (0.37) | MAPTSMYD2SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL2993811 | 0.71 | PER2 (0.40) | SMYD2PER2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| EP-2167499-B1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2167499-B1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| EP-2167499-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008155069-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1626969-A1 | HETEROCYCLIC COMPOUNDS | Bayer HealthCare AG (DE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004101557-A1 | HETEROCYCLIC COMPOUNDS | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, OXA1L, PPOX | MAPT 4810/4885SMYD2 4432/4885SMN1; SMN2 2496/4885 |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | XDH, OXA1L, PPOX | MAPT 4828/4885SMYD2 4461/4885SMN1; SMN2 2273/4885 |
| US-20070066615-A1 | Heterocyclic compounds | F2, SERPINC1, TFPI | MAPT 4025/4885SMYD2 2590/4885SMN1; SMN2 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.